Medtronic Announces Voluntary Recall of Diabetes Infusion Sets

September 11, 2017

Medtronic plc (NYSE:MDT) announced today that it has started to inform patients worldwide of a voluntary recall of specific lots of infusion sets used with all models of Medtronic insulin pumps. The recall is related to a certain discontinued component in these infusion sets and does not include insulin pumps or glucose sensors.

Read more >

Medtronic Announces Outcomes-Based Agreement with Aetna for Type 1 and Type 2 Diabetes Patients

June 26, 2017

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced a new outcomes-based agreement with Aetna (NYSE:AET) for type 1 and type 2 diabetes patients currently on multiple daily insulin injections for their diabetes management. The agreement will measure health outcomes for those patients that choose to transition to pump therapy using a Medtronic insulin pump featuring SmartGuard(TM) Technology, including the new MiniMed(TM) 670G system* - the first and only system that constantly self-adjusts to keep patients' blood sugar levels in range based on their personalized needs.1

Read more >

Medtronic Initiates U.S. Launch of World's First Hybrid Closed Loop System for Type 1 Diabetes

June 7, 2017

The MiniMed(TM) 670G System Features the Company's Most Advanced SmartGuard(TM)HCL Technology and New Guardian(TM) Sensor 3 Medtronic plc (NYSE:MDT), today announced the U.S. launch of the MiniMed(TM) 670G system - the world's first Hybrid Closed Loop system for people with type 1 diabetes. Featuring the company's most advanced SmartGuard(TM) HCL technology and Guardian(TM) Sensor 3, it is the only insulin pump approved by the Food and Drug Administration (FDA) that enables personalized and automated delivery of basal insulin, the background insulin needed to maintain stable blood sugar levels throughout the day and night. The advanced SmartGuard HCL algorithm works in conjunction with the company's most accurate sensor to date - Guardian Sensor 3 - to self-adjust basal insulin delivery every five minutes based on real-time needs. Through this personalized design, the system is able to maximize Time in Range - the amount of time sugar levels stay within a range considered healthy by clinical standards. The system also exclusively features the CONTOUR®NEXT LINK 2.4 blood glucose monitoring system (BGMS) from Ascensia Diabetes Care.

Read more >

Medtronic Announces Scientific Data Presentations at the American Diabetes Association 77th Meeting

June 6, 2017

Medtronic (NYSE:MDT), the global leader in medical technology, today announced its schedule of notable sessions that will be presented at the 77th Scientific Sessions of the American Diabetes Association, in San Diego, June 9-13. A significant portion of the scientific data being presented focuses on Medtronic's insulin pump systems, including the MiniMed(TM) 670G system, the world's first hybrid closed-loop system which will be commercially available this month. Data will also be presented on the Sugar.IQ(TM) app, powered by IBM Watson technology, as well as managing glucose control for patients at Diabeter clinics in the Netherlands.

Read more >

Medtronic EVP & President Hooman Hakami to Speak at Oppenheimer Healthcare Conference

March 16, 2017

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate in the Oppenheimer 27th Annual Healthcare Conference on Tuesday, March 21, 2017, in New York City. Hooman Hakami, executive vice president and group president of Medtronic's Diabetes Group, will answer questions about the company beginning at 8:35 a.m. EDT (7:35 a.m. CDT).

Read more >

View all Announcements >

Media Inquiries

For media inquiries pertaining to the Diabetes Group of Medtronic, please contact:

Janet Kim
Director, Communications

Pamela Reese
Director, Communications

For all other media inquiries please select the appropriate Global Public and Media Relations contact

Media Kits